

Craig M Kessler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7467894/publications.pdf>

Version: 2024-02-01

80
papers

3,598
citations

201385

27
h-index

133063

59
g-index

86
all docs

86
docs citations

86
times ranked

3217
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 129.	3.8	37
2	A randomized phase 3 trial of interferon- β vs hydroxyurea in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2022, 139, 2931-2941.	0.6	45
3	Development of factor IX inhibitor in an adult with severe haemophilia B following COVID-19 vaccination: A case report. <i>Haemophilia</i> , 2022, 28, .	1.0	1
4	Immune thrombocytopenia in the elderly: immunosenescent and clinical diversity. <i>British Journal of Haematology</i> , 2022, 196, 1134-1136.	1.2	1
5	The role of total ankle replacement in patients with haemophilia and end-stage ankle arthropathy: A review. <i>Haemophilia</i> , 2021, 27, 184-191.	1.0	7
6	Thrombocytopenia following Pfizer and Moderna <sc>SARS-CoV-2</sc> vaccination. <i>American Journal of Hematology</i> , 2021, 96, 534-537.	2.0	331
7	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant) Tj ETQq1 1 0.784314 rgBT /Overl 2021, 27, 911-920.	1.0	5
8	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. <i>Haemophilia</i> , 2021, 27, 921-931.	1.0	7
9	Emicizumab for the Treatment of Acquired Hemophilia a: A Multicenter US Case Series. <i>Blood</i> , 2021, 138, 496-496.	0.6	7
10	Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency during Surgery or Childbirth. <i>Blood</i> , 2021, 138, 3238-3238.	0.6	0
11	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 586-586.	0.6	1
12	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. <i>Haemophilia</i> , 2020, 26, 966-974.	1.0	4
13	International recommendations on the diagnosis and treatment of acquired hemophilia A. <i>Haematologica</i> , 2020, 105, 1791-1801.	1.7	182
14	Acquired Coagulopathy With Immune Checkpoint Inhibitors: An Underrecognized Association Between Inflammation and Coagulation. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100049.	0.6	5
15	Highlights in nonmalignant hematology from the 2019 American Society of Hematology meeting. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18, 86-88.	0.3	0
16	Efficacy and safety of simoctocog alfa (Nuwiq [®]) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071985847.	1.1	18
17	Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement. <i>Haemophilia</i> , 2019, 25, 969-978.	1.0	24
18	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , 2019, 134, 1498-1509.	0.6	123

#	ARTICLE	IF	CITATIONS
19	Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1343-1345.	0.6	17
20	Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1144-1152.	1.9	34
21	Publishing in Haemophilia. <i>Haemophilia</i> , 2019, 25, 181-182.	1.0	2
22	Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. <i>Blood Reviews</i> , 2019, 35, 43-50.	2.8	57
23	Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. <i>Haemophilia</i> , 2019, 25, 213-220.	1.0	31
24	The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. <i>Haemophilia</i> , 2019, 25, 33-44.	1.0	63
25	Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings. <i>Blood</i> , 2019, 134, 2943-2943.	0.6	4
26	Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. <i>Thrombosis and Haemostasis</i> , 2018, 118, 451-460.	1.8	22
27	Impact of hemophilia B on quality of life in affected men, women, and caregivers—Assessment of patient-reported outcomes in the HERO study. <i>European Journal of Haematology</i> , 2018, 100, 592-602.	1.1	30
28	Patient-reported outcomes and joint status across subgroups of US adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (PFIQ) study. <i>European Journal of Haematology</i> , 2018, 100, 14-24.	1.1	10
29	Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (PFIQ) study. <i>European Journal of Haematology</i> , 2018, 100, 5-13.	1.1	37
30	Treatment of Venous Thromboembolism in Elite Athletes: A Suggested Approach to Individualized Anticoagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 813-822.	1.5	7
31	Reliability and validity of patient-reported outcome instruments in US adults with hemophilia B and caregivers in the HERO study. <i>European Journal of Haematology</i> , 2018, 101, 781-790.	1.1	7
32	Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim. <i>Blood</i> , 2018, 132, 735-735.	0.6	11
33	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2018, 132, 3032-3032.	0.6	6
34	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , 2018, 132, 577-577.	0.6	39
35	Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study. <i>Blood</i> , 2018, 132, 383-383.	0.6	1
36	Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study. <i>Blood</i> , 2018, 132, 2479-2479.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Feasibility of the Von Willebrand disease PREVENT trial. <i>Thrombosis Research</i> , 2017, 156, 8-13.	0.8	9
38	Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) study. <i>European Journal of Haematology</i> , 2017, 98, 5-17.	1.1	25
39	Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1831-1839.	0.8	27
40	The Coags Uncomplicated App: Fulfilling Educational Gaps Around Diagnosis and Laboratory Testing of Coagulation Disorders. <i>JMIR Medical Education</i> , 2017, 3, e6.	1.2	3
41	Assessment of acquired hemophilia patient demographics in the United States. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 761-769.	0.5	39
42	A second retrospective database analysis confirms prior findings of apparent increased cardiovascular comorbidities in hemophilia A in the United States. <i>American Journal of Hematology</i> , 2016, 91, E298-9.	2.0	11
43	Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience. <i>Expert Review of Hematology</i> , 2016, 9, 1151-1164.	1.0	2
44	Impact of Mild to Severe Hemophilia B on Quality of Life Including Pain and Functional Abilities in Affected Men/Women and Caregivers of Affected Boys/Girls: Analysis of Patient Reported Outcomes in the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study. <i>Blood</i> , 2016, 128, 251-251.	0.6	1
45	Relapsing Thrombotic Thrombocytopenic Purpura: A Single Center Experience. <i>Blood</i> , 2016, 128, 3732-3732.	0.6	0
46	Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentor, 2 Trial. <i>Blood</i> , 2016, 128, 2573-2573.	0.6	0
47	Acquired haemophilia: an overview for clinical practice. <i>European Journal of Haematology</i> , 2015, 95, 36-44.	1.1	82
48	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. <i>Blood</i> , 2014, 123, 3887-3894.	0.6	112
49	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. <i>Blood</i> , 2014, 124, 2836-2836.	0.6	4
50	Economic Comparison Of Treating Hemophilia Patients Who Have Developed Inhibitors Via Immune Tolerance Induction Versus Prophylaxis and On-Demand Treatment With Bypassing Agents. <i>Blood</i> , 2013, 122, 422-422.	0.6	0
51	Use of objective efficacy criteria for evaluation of von willebrand factor/factor VIII concentrates. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 262-267.	0.5	4
52	US Experience with Recombinant Factor VIIa (rFVIIa) for Surgery in Acquired Hemophilia (AH): Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry. <i>Blood</i> , 2012, 120, 3372-3372.	0.6	5
53	Use of Recombinant Factor VIIa (rFVIIa) for Acute Bleeding Episodes in Acquired Hemophilia: Final Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Study. <i>Blood</i> , 2012, 120, 4624-4624.	0.6	4
54	The Hemostasis and Thrombosis Research Society (HTRS) Registry Study of Acquired Hemophilia: Assessment of AH Patient Demographics in the US. <i>Blood</i> , 2012, 120, 4625-4625.	0.6	1

#	ARTICLE	IF	CITATIONS
55	The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. <i>Thrombosis and Haemostasis</i> , 2011, 106, 279-288.	1.8	30
56	Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,. <i>Blood</i> , 2011, 118, 3281-3281.	0.6	9
57	Recombinant Factor VIIa (rFVIIa) Is Safe and Effective When Used to Treat Acute Bleeding Episodes and to Prevent Bleeding During Surgery in Patients with Acquired Hemophilia: Updated Assessment From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Database,. <i>Blood</i> , 2011, 118, 3374-3374.	0.6	2
58	Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. <i>BMC Research Notes</i> , 2010, 3, 161.	0.6	149
59	Recent developments in topical thrombins. <i>Thrombosis and Haemostasis</i> , 2009, 102, 15-24.	1.8	33
60	Prevention of Venous Thromboembolism in Hospitalized Medical Patients. <i>Cancer Investigation</i> , 2009, 27, 17-27.	0.6	1
61	International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. <i>Haematologica</i> , 2009, 94, 566-575.	1.7	362
62	The Link Between Cancer and Venous Thromboembolism. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, S3-S7.	0.6	45
63	Treatment of Acute Bleeds in Acquired Hemophilia: An Updated Analysis From the Hemophilia and Thrombosis Research Society (HTRS) Registry.. <i>Blood</i> , 2009, 114, 3499-3499.	0.6	0
64	Treatment of Acute Bleeds in Acquired Hemophilia: Analysis from the Hemophilia Research Society (HRS) and Hemophilia and Thrombosis Research Society (HTRS) Registry.. <i>Blood</i> , 2008, 112, 2285-2285.	0.6	0
65	Advances in the treatment of hemophilia. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 184-7.	0.3	3
66	A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.. <i>Blood</i> , 2007, 110, 783-783.	0.6	14
67	Von Willebrand Disease (VWD) - A Disease with Dual Factor Deficiencies- Discrepant FVIII:C Pharmacokinetic (PK) Characteristics in a Head to Head Trial of Two VWF/FVIII Concentrates.. <i>Blood</i> , 2007, 110, 2141-2141.	0.6	0
68	Update on Liver Disease in Hemophilia Patients. <i>Seminars in Hematology</i> , 2006, 43, S13-S17.	1.8	9
69	Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2006, 85, 1239-1247.	1.3	35
70	Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. <i>American Journal of Hematology</i> , 2006, 81, 582-589.	2.0	43
71	The Impact of GM-CSF on Arsenic Trioxide (As ₂ O ₃ , Trisenox) Therapy in Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase II Study.. <i>Blood</i> , 2006, 108, 4856-4856.	0.6	1
72	New Perspectives in Hemophilia Treatment. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 429-435.	0.9	49

#	ARTICLE	IF	CITATIONS
73	Antidotes to haemorrhage: recombinant factor VIIa. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 183-197.	0.7	7
74	Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2003, 348, 1425-1434.	13.9	771
75	Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. <i>Blood</i> , 2002, 99, 450-456.	0.6	188
76	Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate. <i>Annals of Internal Medicine</i> , 2002, 137, 884.	2.0	244
77	Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?. <i>Intensive Care Medicine</i> , 2002, 28, s228-s234.	3.9	22
78	New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. <i>Current Opinion in Hematology</i> , 2000, 7, 408-413.	1.2	34
79	Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate. <i>American Journal of Hematology</i> , 1992, 40, 210-215.	2.0	33
80	Anticoagulation and Thrombolytic Therapy. <i>Chest</i> , 1989, 95, 245S-256S.	0.4	6